secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001628280-24-048173
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M
--------------------------------------------------------------------------------

- FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.
- Gross margin improved to 45.1% in Q4FY24 (from 36.6%); net loss narrowed to $34.7M ($0.59/share) from $46.2M ($0.81/share).
- FY2025 guidance: revenue $367M-$377M; targeting 50% gross margin by Q4FY25.
- Adjusted EBITDA improved to -$93.5M FY2024 vs -$147.3M FY2023; cash $276.4M at year-end.
- Entered $15M royalty purchase agreement with XOMA; launched FlexPrep NGS kit with proprietary enzyme.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024048173/0001628280-24-048173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024048173/twist-20241118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-048173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer